晶晨股份(688099.SH):控股股東晶晨控股大宗交易減持1.34%股份
格隆匯6月30日丨晶晨股份(688099.SH)公佈,公司於2023年6月29日收到公司控股股東晶晨控股發來的《關於通過大宗交易方式減持的吿知函》。晶晨控股於2023年5月19日及2023年6月29日期間,通過大宗交易的方式減持其所持有的公司無限售流通股數量557.09萬股,佔公司總股本的1.34%。另外,因公司限制性股票激勵計劃歸屬上市,晶晨控股所持股份被動稀釋。本次權益變動後,晶晨控股持有公司無限售流通股121,350,840股,佔公司總股本的29.16%,仍是公司控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.